Welcome to SJGLE.com! |Register for free|log in
Welcome to SJGLE.com! |Register for free|log in
Related Searches: Tea Vitamin Nutrients Ingredients paper cup packing
Nestlé has doubled down on its bet on a new therapy for peanut allergies.
Palforzia, from Aimmune Therapeutics Inc., treats peanut allergies by reducing the trauma suffered by allergic individuals upon exposure to peanuts. A powder made from peanuts, Palforzia is administered in escalating doses over an 11-month period. It does not cure peanut allergies, and sufferers must continue to avoid peanuts, but it mitigates the potentially fatal consequences of peanut exposure.
The FDA approved Palforzia on Jan. 31, and Aimmune announced on Feb. 5 that Nestlé had invested another $200 million in the drug. Nestlé had previously made investments totaling $273 million.
Nestlé’s involvement is seen as a way to increase revenue from its Health Science division and pivot away from food, wher sales have stagnated.
E-newsletter
Tags
Recommended Products
Sodium Diacetate
VC+E Chewable Tablet
32 Heads Mixing Multihead Weigher
MOS（Malto Oligosaccharides）
ASP200 Aseptic Filling Machine
GM-020 probiotic capsules
Fuzhu production line
Genmont Li-Jian-Min probiotic capsules
Collagen peptide solid drink
